|Certifications and Research
FANGOCUR has met international certification standards and is approved for medical use
There are a number of challenges surrounding the manufacture of products that are intended for medical use. The first is the speed of innovation combined with an ever-advancing market. Companies producing therapeutic products have to keep up with evolving requirements in order to best meet the needs of people using their products. Ensuring maximum benefit to customers while adhering to stringent quality standards are crucial to participants in this competitive industry.
A certification is awarded by an independent accreditation organisation, which confirms that products and production procedures, including quality control, meet certain strict rules and legal requirements – as FANGOCUR is based in Austria, we are bound by EU regulations. Therefore a company’s adherence to stringent criteria for certification as a medical product validates quality at all levels.
FANGOCUR regularly undergoes rigorous inspection procedures and has maintained approval for medical use for over 10 years without interruption.
In summary, you can truly rely on the quality of our products!
The described effects of the FANGOCUR product that have been certified for medical use are, for the most part, not based on the results of human clinical trials, thus they are not without controversy in the scientific field of pharmacology. Nonetheless medical literature, therapeutic experience and research does exist that attributes numerous positive effects and various medical applications to the primary substances contained in healing clay.
Our medical products are legally approved for the treatment of medical indications as described on this website.
Verification of effectiveness is based on the following studies, the full text of which we are unfortunately not allowed to make available due laws pertaining to competition.
|Studies pertaining to skin application (e.g. clay masks)
• Balneological medical statement on the use of “fangocur” products made from Gossendorf bentonite for dermatological purposes, a.o. Univ.-Prof. Dr. Wolfgang Marktl, Medical University of Vienna, Centre for Physiology and Pathophysiology, 26 July 2006.
• Balneological medical statement on the use of Gossendorf bentonite for rosacea, a.o. Univ.-Prof. Dr. Wolfgang Marktl, Specialist in Medical Performance Physiology, Vienna International Academy for Holistic Medicine, 5 December 2012.
• Patient observations in the use of Gossendorf fango in the form of the “Acne Mineral Mask” from fangocur for the treatment of rosacea, 25 patients included, September 2011 to February 2012; results: significant effectiveness of over 90%, elimination of symptoms in 40.91%, reduced symptoms in 27.27%, Dr. med. univ. Elke Spreizer, Specialist Physician in Dermatology, Specialist Physician in Skin Diseases and Sexually Transmitted Diseases, 9 December 2012. [Note: The patient observations did not involve randomised, placebo-controlled, double-blinded studies, thus this is not scientific proof of efficacy. The respective observations were carried out in preparation for a scientific study.]
|Other general studies / literature about fangocur healing clay
• Styrian Vulkanton Erupton (i.e. the previous designation for Gossendorf fango), first known published text on healing clay, Dr. Gottfried Kopetzky, legally authorised expert in geology, Minerological Newsletter of Joanneum Graz, 2, 46-52, 1961.
• Styrian bentonite as a healing peloid clay, peloid analysis, Inorganic and Analytical Chemistry Institute of the University of Graz, Dr. J. Raber, 1977.
• Medical Balneological report on the usability of Gossendorf volcanic clay in the form of mud packs, Institute of Pharmacodynamics and Toxicology of the University of Graz, Prof. Dr. W. R. Kukovetz, 16 November 1978.
• Assessment of the Styrian Provincial Government of 13 July 1982, recognition of Gossendorf fango as a naturally occurring healing substance according to the Styrian Natural Healing and Health Spa law.
• Clinical evaluation according to MEDDEV 2.7.1, rev. 4 concerning Gossendorf fango, OFI Austrian Institute for Research, Technology and Innovation GmbH, DI Gabriele Ettenberger-Bornberg, BA, Dipl. Ing. Dr. Elisabeth Mertl, Mag. Harald Huber, a.o. Univ.-Prof. Dr. Wolfgang Marktl, 5 July 2019.
• Examination of in vitro cytotoxicity according to EN ISO 10993 part 5 and part 12, Bentomed, OFI Austrian Institute for Research, Technology and Innovation GmbH, 12 February 2012.
Gossendorf Vulkanton, full analysis 2019, Karl-Franzens University Graz, Institute for Chemistry, field of analytical chemistry, Assoc. Prof. Mag. Dr. Georg Raber, 29 August 2019.